---
document_datetime: 2025-12-02 05:25:35
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nevanac.html
document_name: nevanac.html
version: success
processing_time: 0.1088699
conversion_datetime: 2025-12-28 12:31:57.621892
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nevanac

[RSS](/en/individual-human-medicine.xml/66578)

##### Authorised

This medicine is authorised for use in the European Union

nepafenac Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nevanac](#news-on)
- [More information on Nevanac](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Nevanac. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nevanac.

Expand section

Collapse section

## What is Nevanac?

Nevanac is an eye drop suspension that contains the active substance nepafenac (1 and 3 mg/ml).

## What is Nevanac used for?

Nevanac is used in adults to prevent and treat the pain and inflammation that can occur after an operation to remove a cataract from the eye.

Nevanac is also used to reduce the risk of macular oedema (swelling in the macula, the central part of the retina at the back of the eye) that can occur after cataract surgery in adult diabetes patients.

The medicine can only be obtained with a prescription.

## How is Nevanac used?

One drop of Nevanac is given into the affected eye(s), either three times a day with the 1 mg/ml strength, or once a day if using the 3 mg/ml strength. Treatment should begin one day before the cataract operation. Treatment is continued after the operation for 2 to 3 weeks when used to prevent pain and inflammation, or up to 60 days when used to reduce the risk of macular oedema. An extra drop should be given 30 to 120 minutes before the operation begins. If other eye medicines are also being used, there should be a gap of at least five minutes between using each medicine.

## How does Nevanac work?

The active substance in Nevanac, nepafenac, is a 'prodrug' of amfenac. This means that it is converted into amfenac in the eye. Amfenac is a non?steroidal anti?inflammatory drug (NSAID). It works by blocking an enzyme called cyclo-oxygenase, which produces prostaglandins, substances that are involved in the inflammation process. By reducing the production of prostaglandins in the eye, Nevanac can reduce complications caused by eye surgery, such as inflammation, pain and swelling.

## How has Nevanac been studied?

For the prevention and treatment of pain and inflammation, Nevanac 1 mg/ml has been studied in four main studies involving a total of 1,201 patients undergoing cataract surgery. One study compared Nevanac 1 mg/ml used once, twice or three times a day with placebo (dummy eye drops) in 220 patients. Another three studies, in a total of 981 patients, compared Nevanac used three times a day, either with placebo, with ketorolac eye drops (another NSAID) or with both placebo and ketorolac. The main measure of effectiveness was either the proportion of patients in whom treatment had been successful (with no or few signs of inflammation in the eye), or the proportion of patients whose treatment had failed (with signs of moderate or severe inflammation in the eye). These were measured two weeks after surgery.

The company also carried out studies to show that Nevanac 3 mg/ml given once a day was more effective than placebo and had the same effect in preventing and treating pain and inflammation as Nevanac 1 mg/ml given three times a day.

For reducing the risk of macular oedema, Nevanac has been compared with placebo in three main studies involving 1483 diabetes patients with retinopathy (damage to the retina) undergoing cataract surgery. The first main study used Nevanac 1 mg/ml whereas the other 2 main studies used Nevanac 3 mg/ml. The main measure of effectiveness was the number of patients who developed macular oedema within 90 days of surgery.

## What benefit has Nevanac shown during the studies?

Nevanac was more effective than placebo and as effective as ketorolac in reducing signs of inflammation. In the study comparing different numbers of drops daily, the patients using Nevanac 1 mg/ml three times a day had the lowest failure rate. When Nevanac was compared with placebo, around 70% of the patients using Nevanac had no signs of inflammation after two weeks, compared with 17% to 59% of those using placebo. In the study comparing Nevanac with ketorolac, around 65% of both groups of patients showed no or few signs of inflammation.

In diabetes patients, Nevanac was more effective than placebo in reducing the risk of macular oedema. In the first study, 3.2% of patients taking Nevanac 1 mg/ml developed macular oedema (4 out of 125), compared with 16.7% of patients taking placebo (21 out of 126). In the second and third study, 2.3% and 5.9% of patients taking Nevanac 3 mg/ml developed macular oedema, respectively, compared with between 17.3% and 14.3% of patients taking placebo.

## What is the risk associated with Nevanac?

The most common side effects with Nevanac (seen in up to 1 in 100 patients) are inflammation of the surface of the eye, defects in the cornea, the sensation of a foreign body in the eye, and crust forming at edge on the eyelids. For the full list of all side effects reported with Nevanac, see the package leaflet.

Nevanac must not be used in people who are hypersensitive (allergic) to nepafenac, to any of the other ingredients or to other NSAIDs. Like other NSAIDs, Nevanac must not be used in patients who have previously had an attack of asthma, hives or inflammation of the nasal passages when they take aspirin or other NSAIDs. Nevanac contains benzalkonium chloride, which is known to discolour soft contact lenses. Additionally, contact lens wear is not recommended during the postoperative period following cataract surgery. Therefore, patients should be advised not to wear contact lenses during treatment with Nevanac.

## Why has Nevanac been approved?

The CHMP decided that Nevanac's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Nevanac?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nevanac have also been included in the summary of product characteristics and the package leaflet.

## Other information about Nevanac

The European Commission granted a marketing authorisation valid throughout the European Union for Nevanac on 11 December 2007.

For more information about treatment with Nevanac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Nevanac : EPAR - Summary for the public

Reference Number: EMA/366273/2013

English (EN) (72.99 KB - PDF)

**First published:** 14/01/2008

**Last updated:** 09/09/2016

[View](/en/documents/overview/nevanac-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-292)

български (BG) (100.21 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/bg/documents/overview/nevanac-epar-summary-public_bg.pdf)

español (ES) (71.99 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/es/documents/overview/nevanac-epar-summary-public_es.pdf)

čeština (CS) (72.99 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/cs/documents/overview/nevanac-epar-summary-public_cs.pdf)

dansk (DA) (71.36 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/da/documents/overview/nevanac-epar-summary-public_da.pdf)

Deutsch (DE) (73.55 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/de/documents/overview/nevanac-epar-summary-public_de.pdf)

eesti keel (ET) (71.37 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/et/documents/overview/nevanac-epar-summary-public_et.pdf)

ελληνικά (EL) (101.56 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/el/documents/overview/nevanac-epar-summary-public_el.pdf)

français (FR) (73.38 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/fr/documents/overview/nevanac-epar-summary-public_fr.pdf)

hrvatski (HR) (94.22 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/hr/documents/overview/nevanac-epar-summary-public_hr.pdf)

italiano (IT) (71.98 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/it/documents/overview/nevanac-epar-summary-public_it.pdf)

latviešu valoda (LV) (96.15 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/lv/documents/overview/nevanac-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (97.8 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/lt/documents/overview/nevanac-epar-summary-public_lt.pdf)

magyar (HU) (92.3 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/hu/documents/overview/nevanac-epar-summary-public_hu.pdf)

Malti (MT) (101.81 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/mt/documents/overview/nevanac-epar-summary-public_mt.pdf)

Nederlands (NL) (71.6 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/nl/documents/overview/nevanac-epar-summary-public_nl.pdf)

polski (PL) (99.26 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/pl/documents/overview/nevanac-epar-summary-public_pl.pdf)

português (PT) (72.27 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/pt/documents/overview/nevanac-epar-summary-public_pt.pdf)

română (RO) (95.1 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/ro/documents/overview/nevanac-epar-summary-public_ro.pdf)

slovenčina (SK) (96.73 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/sk/documents/overview/nevanac-epar-summary-public_sk.pdf)

slovenščina (SL) (93.19 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/sl/documents/overview/nevanac-epar-summary-public_sl.pdf)

Suomi (FI) (71.75 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/fi/documents/overview/nevanac-epar-summary-public_fi.pdf)

svenska (SV) (72.17 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

09/09/2016

[View](/sv/documents/overview/nevanac-epar-summary-public_sv.pdf)

Nevanac : EPAR - Risk-management-plan summary

English (EN) (47.29 KB - PDF)

**First published:** 06/07/2020

[View](/en/documents/rmp-summary/nevanac-epar-risk-management-plan-summary_en.pdf)

## Product information

Nevanac : EPAR - Product Information

English (EN) (414.02 KB - PDF)

**First published:** 13/02/2009

**Last updated:** 08/09/2025

[View](/en/documents/product-information/nevanac-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-67)

български (BG) (466.42 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/bg/documents/product-information/nevanac-epar-product-information_bg.pdf)

español (ES) (405.87 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/es/documents/product-information/nevanac-epar-product-information_es.pdf)

čeština (CS) (479.36 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/cs/documents/product-information/nevanac-epar-product-information_cs.pdf)

dansk (DA) (413.83 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/da/documents/product-information/nevanac-epar-product-information_da.pdf)

Deutsch (DE) (414.16 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/de/documents/product-information/nevanac-epar-product-information_de.pdf)

eesti keel (ET) (367.08 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/et/documents/product-information/nevanac-epar-product-information_et.pdf)

ελληνικά (EL) (504.12 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/el/documents/product-information/nevanac-epar-product-information_el.pdf)

français (FR) (484.86 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/fr/documents/product-information/nevanac-epar-product-information_fr.pdf)

hrvatski (HR) (486.05 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/hr/documents/product-information/nevanac-epar-product-information_hr.pdf)

íslenska (IS) (414.04 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/is/documents/product-information/nevanac-epar-product-information_is.pdf)

italiano (IT) (872.89 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/it/documents/product-information/nevanac-epar-product-information_it.pdf)

latviešu valoda (LV) (463.69 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/lv/documents/product-information/nevanac-epar-product-information_lv.pdf)

lietuvių kalba (LT) (475.43 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/lt/documents/product-information/nevanac-epar-product-information_lt.pdf)

magyar (HU) (495.22 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/hu/documents/product-information/nevanac-epar-product-information_hu.pdf)

Malti (MT) (555.03 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/mt/documents/product-information/nevanac-epar-product-information_mt.pdf)

Nederlands (NL) (430.37 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/nl/documents/product-information/nevanac-epar-product-information_nl.pdf)

norsk (NO) (407.22 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/no/documents/product-information/nevanac-epar-product-information_no.pdf)

polski (PL) (485.96 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/pl/documents/product-information/nevanac-epar-product-information_pl.pdf)

português (PT) (416.87 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/pt/documents/product-information/nevanac-epar-product-information_pt.pdf)

română (RO) (487.46 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/ro/documents/product-information/nevanac-epar-product-information_ro.pdf)

slovenčina (SK) (495.08 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/sk/documents/product-information/nevanac-epar-product-information_sk.pdf)

slovenščina (SL) (463.13 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/sl/documents/product-information/nevanac-epar-product-information_sl.pdf)

Suomi (FI) (400.5 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/fi/documents/product-information/nevanac-epar-product-information_fi.pdf)

svenska (SV) (405.14 KB - PDF)

**First published:**

13/02/2009

**Last updated:**

08/09/2025

[View](/sv/documents/product-information/nevanac-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000294093 05/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nevanac : EPAR - All Authorised presentations

English (EN) (18.21 KB - PDF)

**First published:** 14/01/2008

**Last updated:** 23/12/2014

[View](/en/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-70)

български (BG) (38.97 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/bg/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.42 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/es/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_es.pdf)

čeština (CS) (33.27 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/cs/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.61 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/da/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.77 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/de/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.8 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/et/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.41 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/el/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_el.pdf)

français (FR) (18.33 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/fr/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (32.31 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/hr/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (20.22 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/is/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.52 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/it/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.22 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/lv/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (32.69 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/lt/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (24.78 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/hu/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.79 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/mt/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.19 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/nl/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (21.18 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/no/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_no.pdf)

polski (PL) (32.8 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/pl/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.15 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/pt/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.17 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/ro/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (36.09 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/sk/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.82 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/sl/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (21.11 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/fi/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (21.86 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/12/2014

[View](/sv/documents/all-authorised-presentations/nevanac-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nevanac Active substance nepafenac International non-proprietary name (INN) or common name nepafenac Therapeutic area (MeSH)

- Pain, Postoperative
- Ophthalmologic Surgical Procedures

Anatomical therapeutic chemical (ATC) code S01BC10

### Pharmacotherapeutic group

Ophthalmologicals

### Therapeutic indication

Nevanac is indicated for:

- prevention and treatment of postoperative pain and inflammation associated with cataract surgery;
- reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

## Authorisation details

EMA product number EMEA/H/C/000818 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 11/12/2007 Revision 20

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nevanac : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (136.05 KB - PDF)

**First published:** 08/09/2025

[View](/en/documents/procedural-steps-after/nevanac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Nevanac : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (179.22 KB - PDF)

**First published:** 13/02/2009

**Last updated:** 08/09/2025

[View](/en/documents/procedural-steps-after/nevanac-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Nevanac-H-C-818-II-0032: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/167525/2016

English (EN) (1.87 MB - PDF)

**First published:** 09/09/2016

**Last updated:** 09/09/2016

[View](/en/documents/variation-report/nevanac-h-c-818-ii-0032-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Nevanac

Adopted

Reference Number: EMA/CHMP/421658/2016

English (EN) (72.25 KB - PDF)

**First published:** 24/06/2016

**Last updated:** 24/06/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nevanac_en.pdf-0)

Nevanac-H-C-818-PSUV-0029 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/230129/2015

English (EN) (73.53 KB - PDF)

**First published:** 03/06/2015

**Last updated:** 03/06/2015

[View](/en/documents/scientific-conclusion/nevanac-h-c-818-psuv-0029-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Nevanac-H-C-818-X-0016 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/393189/2013

English (EN) (480.82 KB - PDF)

**First published:** 16/08/2013

**Last updated:** 16/08/2013

[View](/en/documents/variation-report/nevanac-h-c-818-x-0016-epar-assessment-report-extension_en.pdf)

Nevanac-H-C-818-II-0007-G : EPAR - Assessment Report - Variation

Adopted

English (EN) (798.64 KB - PDF)

**First published:** 09/02/2012

**Last updated:** 09/02/2012

[View](/en/documents/variation-report/nevanac-h-c-818-ii-0007-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Nevanac

Adopted

Reference Number: EMA/CHMP/651318/2011

English (EN) (57.28 KB - PDF)

**First published:** 18/11/2011

**Last updated:** 18/11/2011

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nevanac_en.pdf)

## Initial marketing authorisation documents

Nevanac : EPAR - Procedural steps taken before authorisation

English (EN) (17.39 KB - PDF)

**First published:** 14/01/2008

**Last updated:** 14/01/2008

[View](/en/documents/procedural-steps/nevanac-epar-procedural-steps-taken-authorisation_en.pdf)

Nevanac : EPAR - Scientific Discussion

English (EN) (580.08 KB - PDF)

**First published:** 14/01/2008

**Last updated:** 14/01/2008

[View](/en/documents/scientific-discussion/nevanac-epar-scientific-discussion_en.pdf)

#### News on Nevanac

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2016) 24/06/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 November 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-november-2011) 18/11/2011

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC000818II0032) (variation II/0032)

#### More information on Nevanac

- [EMEA-000913-PIP01-10 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000913-pip01-10)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/09/2025

## Share this page

[Back to top](#main-content)